U.S. Markets open in 51 mins
  • S&P Futures

    3,274.50
    -0.50 (-0.02%)
     
  • Dow Futures

    26,993.00
    -62.00 (-0.23%)
     
  • Nasdaq Futures

    11,025.50
    +36.50 (+0.33%)
     
  • Russell 2000 Futures

    1,480.00
    -2.80 (-0.19%)
     
  • Crude Oil

    39.35
    +0.04 (+0.10%)
     
  • Gold

    1,911.90
    +1.30 (+0.07%)
     
  • Silver

    24.33
    -0.06 (-0.25%)
     
  • EUR/USD

    1.1751
    -0.0022 (-0.1880%)
     
  • 10-Yr Bond

    0.6680
    -0.0030 (-0.45%)
     
  • Vix

    28.11
    +2.28 (+8.83%)
     
  • GBP/USD

    1.2804
    -0.0013 (-0.1012%)
     
  • BTC-USD

    10,481.00
    +43.27 (+0.41%)
     
  • CMC Crypto 200

    213.31
    -22.27 (-9.45%)
     
  • FTSE 100

    5,824.04
    +19.75 (+0.34%)
     
  • Nikkei 225

    23,360.30
    +40.90 (+0.18%)
     

Xencor to Host First Quarter 2020 Financial Results Webcast and Conference Call on May 7, 2020

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, today announced that it will release first quarter 2020 financial results after the market closes on Thursday, May 7, 2020.

Xencor management will host a webcast and conference call the same day at 4:30 p.m. ET (1:30 p.m. PT) to discuss the financial results and provide a corporate update.

The live call may be accessed by dialing (877) 359-9508 for domestic callers or (224) 357-2393 for international callers and referencing conference ID number 6686425. A live webcast of the conference call will be available under "Events & Presentations" in the Investors section of the Company's website located at www.xencor.com. The webcast will be archived on the company website for 30 days.

About Xencor, Inc.

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases. Currently, 17 candidates engineered with Xencor's XmAb® technology are in clinical development internally and with partners. Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200430005834/en/

Contacts

Charles Liles
626-737-8118
cliles@xencor.com

Media Contact
Jason I. Spark
Canale Communications
619-849-6005
jason@canalecomm.com